Biography & Research:
I have a strong background in medicinal chemistry, drug discovery and pharmacology areas. I worked on a variety of projects driven by structure activity relationships (SAR) and hit-to-lead synthesis in Emory Chemical Biology Discovery Center, subsequently Emory Institute for Drug Discovery. I designed and synthesized several preclinical lead candidates, interacted with multidisciplinary teams including bioinformatics, high-throughput screening and drug metabolism and pharmacokinetics (DMPK) to study bio-structural, biochemical and pharmacological properties of small molecules in the past. Since 2011, I have been developing EP2 antagonists for treatment of CNS diseases such as status epilepticus and epilepsy. My current research goals are to investigate neuroinflammation and the development of therapeutic agents for Alzheimer’s disease and post-traumatic epilepsy by targeting a single prostanoid receptor EP2. I have demonstrated my research experience with over 60 peer-reviewed publications in a variety of journals with a current web of science h-index = 18.